Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
Arends EJ, Zlei M, Tipton CM, Cotic J, Osmani Z, de Bie FJ, Kamerling SWA, van Maurik A, Dimelow R, Gregan YI, Fox NL, Rabelink TJ, Roth DA, Sanz I, van Dongen JJM, van Kooten C, Teng YKO. Arends EJ, et al. Among authors: fox nl. Rheumatology (Oxford). 2024 Sep 1;63(9):2387-2398. doi: 10.1093/rheumatology/keae286. Rheumatology (Oxford). 2024. PMID: 38775637 Free PMC article.
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D. Stohl W, et al. Among authors: fox nl. Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7. Arthritis Rheumatol. 2017. PMID: 28118533 Free PMC article. Clinical Trial.
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D. Doria A, et al. Among authors: fox nl. Arthritis Rheumatol. 2018 Aug;70(8):1256-1264. doi: 10.1002/art.40511. Epub 2018 Jun 15. Arthritis Rheumatol. 2018. PMID: 29671280 Free PMC article. Clinical Trial.
10 Years of belimumab experience: What have we learnt?
Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones-Leone A, Rubin B, Burriss SW, Gairy K, Maurik AV, Roth DA. Levy RA, et al. Among authors: fox nl. Lupus. 2021 Oct;30(11):1705-1721. doi: 10.1177/09612033211028653. Epub 2021 Jul 8. Lupus. 2021. PMID: 34238087 Free PMC article. Review.
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, Dall'Era M, Furie R, Fox NL, Gilbride JA, Hammer A, Ginzler EM, Gonzalez-Rivera T, Levy RA, Merrill JT, Quasny H, Roth DA, Stohl W, van Vollenhoven R, Wallace DJ, Petri M. Urowitz MB, et al. Among authors: fox nl. Arthritis Care Res (Hoboken). 2022 Nov;74(11):1822-1828. doi: 10.1002/acr.24901. Epub 2022 Aug 4. Arthritis Care Res (Hoboken). 2022. PMID: 35439360 Free PMC article. Review.
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.
Aranow C, Allaart CF, Amoura Z, Bruce IN, Cagnoli PC, Chatham WW, Clark KL, Furie R, Groark J, Urowitz MB, van Vollenhoven R, Daniels M, Fox NL, Gregan YI, Henderson RB, van Maurik A, Ocran-Appiah JC, Oldham M, Roth DA, Shanahan D, Tak PP, Teng YO. Aranow C, et al. Among authors: fox nl. Ann Rheum Dis. 2024 Oct 21;83(11):1502-1512. doi: 10.1136/ard-2024-225686. Ann Rheum Dis. 2024. PMID: 39159997 Free PMC article. Clinical Trial.
55 results